Pediatric Precursor B-Cell Lymphoblastic Malignancies: From Extramedullary to Medullary Involvement.
B-cell acute lymphoblastic leukemia
B-cell lymphoblastic lymphoma
BCP-ALL
BCP-LBL
NHL
disease spectrum
non-Hodgkin lymphoma
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
12 Aug 2022
12 Aug 2022
Historique:
received:
24
06
2022
revised:
22
07
2022
accepted:
10
08
2022
entrez:
26
8
2022
pubmed:
27
8
2022
medline:
27
8
2022
Statut:
epublish
Résumé
B-cell lymphoblastic lymphoma (BCP-LBL) and B-cell acute lymphoblastic leukemia (BCP-ALL) are the malignant counterparts of immature B-cells. BCP-ALL is the most common hematological malignancy in childhood, while BCP-LBL accounts for only 1% of all hematological malignancies in children. Therefore, BCP-ALL has been well studied and treatment protocols have changed over the last decades, whereas treatment for BCP-LBL has stayed roughly the same. Clinical characteristics of 364 pediatric patients with precursor B-cell malignancies were studied, consisting of BCP-LBL (n = 210) and BCP-ALL (n = 154) patients. Our results indicate that based on the clinical presentation of disease, B-cell malignancies probably represent a spectrum ranging from complete isolated medullary disease to apparent complete extramedullary disease. Hepatosplenomegaly and peripheral blood involvement are the most important discriminators, as both seen in 80% and 95% of the BCP-ALL patients and in 2% of the BCP-LBL patients, respectively. In addition, we show that the overall survival rates in this cohort differ significantly between BCP-LBL and BCP-ALL patients aged 1−18 years (p = 0.0080), and that the outcome for infants (0−1 years) with BCP-LBL is significantly decreased compared to BCP-LBL patients of all other pediatric ages (p < 0.0001).
Identifiants
pubmed: 36010889
pii: cancers14163895
doi: 10.3390/cancers14163895
pmc: PMC9405801
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Foundation KiKa
ID : 393
Références
Cancer Genet Cytogenet. 2009 May;191(1):27-33
pubmed: 19389505
Leuk Lymphoma. 2020 Sep;61(9):2129-2135
pubmed: 32427530
Blood. 2010 Apr 22;115(16):3206-14
pubmed: 20154213
J Clin Oncol. 2019 Sep 1;37(25):2246-2256
pubmed: 31283407
Pediatr Blood Cancer. 2020 Sep;67(9):e28357
pubmed: 32469139
Pediatr Blood Cancer. 2016 Jul;63(7):1214-21
pubmed: 27037853
J Clin Oncol. 2016 Aug 1;34(22):2591-601
pubmed: 27269950
Lancet. 2013 Jun 1;381(9881):1943-55
pubmed: 23523389
Blood. 1986 Jan;67(1):135-40
pubmed: 2934104
J Clin Oncol. 2009 Jul 10;27(20):3363-9
pubmed: 19433688
Leukemia. 2021 Apr;35(4):1001-1011
pubmed: 32820270
Semin Oncol. 1980 Sep;7(3):332-9
pubmed: 7414342
Blood. 2008 May 1;111(9):4477-89
pubmed: 18285545
Int J Hematol. 2013 Jul;98(1):74-88
pubmed: 23702913
Haematologica. 2017 Dec;102(12):2086-2096
pubmed: 28983060
J Clin Oncol. 1985 Nov;3(11):1513-21
pubmed: 3863894
Lancet Oncol. 2013 Mar;14(3):199-209
pubmed: 23395119